US biotech company Amgen (NASDAQ: AMGN) has announced plans to construct a second drug substance manufacturing facility in Holly Springs, North Carolina, raising its total biomanufacturing investment in the region to USD 1.5 billion. This new plant, costing USD 1 billion, follows Amgen’s previously announced commitment of USD 550 million for its first Holly Springs biomanufacturing facility.
Creating Synergy and Jobs in Holly Springs
The establishment of the two plants is expected to create synergistic effects, enhancing Amgen’s biomanufacturing capabilities and contributing to the local economy. In total, the facilities are projected to create 370 new jobs, demonstrating Amgen’s commitment to both innovation and community development.-Fineline Info & Tech
